IDEAYA Biosciences (IDYA) Competitors $25.12 +0.49 (+1.99%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$25.12 0.00 (0.00%) As of 08/22/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IDYA vs. BPMC, ROIV, GRFS, LEGN, RVMD, RYTM, RNA, NUVL, AXSM, and CRSPShould you be buying IDEAYA Biosciences stock or one of its competitors? The main competitors of IDEAYA Biosciences include Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. IDEAYA Biosciences vs. Its Competitors Blueprint Medicines Roivant Sciences Grifols Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences Nuvalent Axsome Therapeutics CRISPR Therapeutics IDEAYA Biosciences (NASDAQ:IDYA) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation. Does the media refer more to IDYA or BPMC? In the previous week, IDEAYA Biosciences had 2 more articles in the media than Blueprint Medicines. MarketBeat recorded 3 mentions for IDEAYA Biosciences and 1 mentions for Blueprint Medicines. IDEAYA Biosciences' average media sentiment score of 1.37 beat Blueprint Medicines' score of 0.00 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Blueprint Medicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate IDYA or BPMC? IDEAYA Biosciences presently has a consensus target price of $48.09, indicating a potential upside of 91.44%. Blueprint Medicines has a consensus target price of $130.00, indicating a potential upside of 0.42%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe IDEAYA Biosciences is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEAYA Biosciences 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.77Blueprint Medicines 0 Sell rating(s) 16 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11 Which has better valuation and earnings, IDYA or BPMC? Blueprint Medicines has higher revenue and earnings than IDEAYA Biosciences. Blueprint Medicines is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEAYA Biosciences$7M314.50-$274.48M-$3.79-6.63Blueprint Medicines$562.12M14.87-$67.09M-$2.47-52.41 Do insiders & institutionals believe in IDYA or BPMC? 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 2.5% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is IDYA or BPMC more profitable? IDEAYA Biosciences has a net margin of 0.00% compared to Blueprint Medicines' net margin of -27.70%. IDEAYA Biosciences' return on equity of -31.42% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets IDEAYA BiosciencesN/A -31.42% -29.45% Blueprint Medicines -27.70%-64.60%-17.22% Which has more volatility and risk, IDYA or BPMC? IDEAYA Biosciences has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. SummaryIDEAYA Biosciences beats Blueprint Medicines on 10 of the 16 factors compared between the two stocks. Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IDYA vs. The Competition Export to ExcelMetricIDEAYA BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.16B$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.09%P/E Ratio-6.6320.8831.1026.05Price / Sales314.50356.38436.12105.98Price / CashN/A43.1937.7358.48Price / Book2.298.129.536.61Net Income-$274.48M-$54.72M$3.26B$265.56M7 Day Performance3.25%2.62%2.11%1.98%1 Month Performance6.31%7.63%5.12%1.33%1 Year Performance-36.39%13.11%31.25%21.15% IDEAYA Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IDYAIDEAYA Biosciences4.5344 of 5 stars$25.12+2.0%$48.09+91.4%-34.5%$2.16B$7M-6.6380Positive NewsBPMCBlueprint Medicines0.5063 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences3.4653 of 5 stars$11.81-0.3%$16.50+39.7%+2.1%$8.06B$29.05M-16.87860Insider TradeGRFSGrifols3.5919 of 5 stars$10.58-1.3%$10.30-2.6%+14.8%$7.37B$7.45B9.0423,822Short Interest ↑LEGNLegend Biotech3.8042 of 5 stars$37.45-0.1%$72.38+93.3%-38.0%$6.89B$627.24M-42.562,609RVMDRevolution Medicines4.417 of 5 stars$36.45+0.4%$69.54+90.8%-14.4%$6.79B$11.58M-8.10250Positive NewsAnalyst RevisionRYTMRhythm Pharmaceuticals3.8397 of 5 stars$98.09+0.5%$101.57+3.5%+133.7%$6.48B$130.13M-32.59140News CoveragePositive NewsRNAAvidity Biosciences3.2033 of 5 stars$44.48-4.3%$67.00+50.6%+8.2%$5.98B$10.90M-12.49190Positive NewsInsider TradeOptions VolumeNUVLNuvalent3.2832 of 5 stars$75.01-1.4%$119.60+59.4%-8.3%$5.48BN/A-15.3140News CoverageAnalyst ForecastInsider TradeAXSMAxsome Therapeutics4.7967 of 5 stars$111.13+1.8%$178.00+60.2%+36.0%$5.45B$385.69M-21.92380News CoveragePositive NewsCRSPCRISPR Therapeutics3.809 of 5 stars$57.59-3.6%$71.60+24.3%+14.4%$5.43B$37.31M-10.61460 Related Companies and Tools Related Companies Blueprint Medicines Alternatives Roivant Sciences Alternatives Grifols Alternatives Legend Biotech Alternatives Revolution Medicines Alternatives Rhythm Pharmaceuticals Alternatives Avidity Biosciences Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives CRISPR Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IDYA) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access